NASDAQ:ELTX Elicio Therapeutics (ELTX) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free ELTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.50▼$10.3850-Day Range N/A52-Week Range N/AVolume53,093 shsAverage Volume49,150 shsMarket Capitalization$103.21 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Elicio Therapeutics alerts: Email Address Elicio Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside0.5% Downside$10.00 Price TargetShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.74) to ($4.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.10 out of 5 starsMedical Sector914th out of 921 stocksPharmaceutical Preparations Industry420th out of 422 stocks 1.3 Analyst's Opinion Consensus RatingElicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageElicio Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Elicio Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.17% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elicio Therapeutics has recently increased by 37.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldElicio Therapeutics does not currently pay a dividend.Dividend GrowthElicio Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Elicio Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders19.70% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.03% of the stock of Elicio Therapeutics is held by institutions.Read more about Elicio Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Elicio Therapeutics are expected to decrease in the coming year, from ($3.74) to ($4.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elicio Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elicio Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElicio Therapeutics has a P/B Ratio of 21.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Elicio Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Elicio TherapeuticsAngion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.Read More Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. ELTX Stock News HeadlinesMay 16 at 9:41 AM | finanznachrichten.deElicio Therapeutics, Inc.: Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 16 at 12:06 AM | investorplace.comELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024May 15, 2024 | globenewswire.comElicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesApril 25, 2024 | globenewswire.comElicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingApril 13, 2024 | finance.yahoo.comRobert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO is the most bullish insider, and their stock value gained 11%last weekApril 5, 2024 | globenewswire.comElicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual MeetingApril 2, 2024 | investorplace.comELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023March 29, 2024 | finanznachrichten.deElicio Therapeutics, Inc.: Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesMarch 29, 2024 | globenewswire.comElicio Therapeutics Reports 2023 Financial Results and Provides Corporate UpdatesMarch 19, 2024 | marketwatch.comElicio Therapeutics Shares Rise 27% After Private PlacementMarch 18, 2024 | msn.comElicio Therapeutics to sell 1.03M shares $5.81 in private placement financingMarch 18, 2024 | globenewswire.comElicio Therapeutics Announces $6.0 Million Private Placement FinancingMarch 6, 2024 | globenewswire.comElicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual MeetingFebruary 23, 2024 | benzinga.comElicio Therapeutics Stock (NASDAQ:ELTX), Short Interest ReportFebruary 5, 2024 | benzinga.comElicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-ImmunotherapyFebruary 5, 2024 | finance.yahoo.comElicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 25, 2024 | finance.yahoo.comElicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid TumorsJanuary 17, 2024 | finance.yahoo.comElicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI SymposiumJanuary 16, 2024 | finance.yahoo.comElicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology ConferenceJanuary 11, 2024 | finanznachrichten.deElicio Therapeutics Inc.: Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer StudyJanuary 9, 2024 | finance.yahoo.comNature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002December 27, 2023 | msn.comElicio Therapeutics director buys stock worth $7MDecember 26, 2023 | msn.comElicio Therapeutics 10% owner purchases stake worth $7.05MDecember 22, 2023 | msn.comElicio Therapeutics to sell 1.2M shares at $5.81 in private placementDecember 22, 2023 | seekingalpha.comELTX Elicio Therapeutics, Inc.See More Headlines Receive ELTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/19/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELTX CUSIPN/A CIK1555192 Webwww.angion.com Phone415-655-4899FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside-0.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-294.17% Return on Assets-129.89% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio1.67 Sales & Book Value Annual Sales$2.30 million Price / Sales44.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book21.38Miscellaneous Outstanding Shares10,270,000Free Float8,216,000Market Cap$103.21 million OptionableNot Optionable Beta0.70 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key CompetitorsAllakosNASDAQ:ALLKConnect BiopharmaNASDAQ:CNTBCyteir TherapeuticsNASDAQ:CYTTAdicet BioNASDAQ:ACETRelmada TherapeuticsNASDAQ:RLMDView All CompetitorsInsiders & InstitutionsCM Management LLCBought 25,000 shares on 5/14/2024Ownership: 0.733%Yekaterina ChudnovskyBought 1,213,000 shares on 12/22/2023Total: $7.05 M ($5.81/share)View All Insider TransactionsView All Institutional Transactions ELTX Stock Analysis - Frequently Asked Questions Should I buy or sell Elicio Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elicio Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ELTX shares. View ELTX analyst ratings or view top-rated stocks. What is Elicio Therapeutics' stock price target for 2024? 2 brokers have issued 1-year target prices for Elicio Therapeutics' shares. Their ELTX share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests that the stock has a possible downside of 0.5%. View analysts price targets for ELTX or view top-rated stocks among Wall Street analysts. When is Elicio Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ELTX earnings forecast. How were Elicio Therapeutics' earnings last quarter? Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its earnings results on Friday, March, 29th. The company reported ($3.77) EPS for the quarter. When did Elicio Therapeutics IPO? Elicio Therapeutics (ELTX) raised $40 million in an initial public offering on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Elicio Therapeutics' major shareholders? Elicio Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include CM Management LLC (0.73%). View institutional ownership trends. This page (NASDAQ:ELTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
